NASDAQ · Key Statistics

Regencell Bioscience Holdings Limited (RGC) P/E Ratio, ROE & Key Statistics

$4.62 NASDAQ: RGC Market Cap $2.29B

Data as of Nov 17, 2026 (intraday, delayed) · Source: Financial Modeling Prep (methodology)

Every valuation, profitability, balance-sheet and per-share figure DeltaScreener holds for Regencell Bioscience Holdings Limited (RGC), each with what it measures. Figures are trailing twelve months or the most recent reported period.

Valuation

MetricValue
P/E ratioShare price divided by earnings per share.-279.45
P/B ratioShare price divided by book value per share.244.40
P/S ratioMarket value divided by annual revenue.0.00
PEG ratioP/E divided by the earnings growth rate.2.82
EV / EBITDAEnterprise value against earnings before interest, tax, depreciation and amortisation.-287.68
EV / RevenueEnterprise value against annual revenue.0.00
Earnings yieldEarnings per share as a percentage of the share price — the inverse of P/E.-0.23%
Free cash flow yieldFree cash flow as a percentage of market value.-0.24%

Profitability

MetricValue
Gross marginRevenue left after the direct cost of goods sold.0.00%
Operating marginRevenue left after operating costs.0.00%
Net marginRevenue left after every cost, including tax and interest.0.00%
Return on equityProfit as a percentage of shareholders’ equity.-160.64%
Return on assetsProfit as a percentage of total assets.-79.45%
Return on capital employedOperating profit against the capital the business uses.-87.44%

Financial health

MetricValue
Current ratioCurrent assets divided by current liabilities. Above 1 means short-term assets cover short-term bills.10.77
Quick ratioThe same, excluding inventory.10.77
Cash ratioCash alone against current liabilities.14.00
Debt to equityTotal borrowings against shareholders’ equity.0.02
Debt to assetsTotal borrowings against total assets.0.00
Interest coverageHow many times operating profit covers the interest bill.0.00

Per share and size

MetricValue
Earnings per shareProfit attributable to each share.−$0.01
Market capitalisationShare price times shares outstanding.$2.29B
Enterprise valueMarket value plus net debt — what it would cost to buy the business outright.$2.61B

Dividend

MetricValue
Dividend yieldAnnual dividend as a percentage of the share price.0.00%

Regencell Bioscience Holdings Limited (RGC) statistics — frequently asked questions

What is Regencell Bioscience Holdings Limited's P/E ratio?

Regencell Bioscience Holdings Limited (RGC) trades on a price-to-earnings ratio of -279.45. A negative P/E means the company reported a loss, so the ratio is not a meaningful valuation measure.

What is Regencell Bioscience Holdings Limited's return on equity?

Regencell Bioscience Holdings Limited (RGC) reports a return on equity of -160.64%, meaning it generated that much profit for every dollar of shareholders' equity.

How much debt does Regencell Bioscience Holdings Limited carry?

Regencell Bioscience Holdings Limited (RGC) has a debt-to-equity ratio of 0.02, which compares total borrowings with shareholders' equity.

P/E and ROE of other Drug Manufacturers - Specialty & Generic stocks

TEVA P/E 94.73ZTS P/E 13.82VTRS ROE -4.24%ELAN ROE -2.24%RDY P/E 39.94ALKS key statisticsAMRX P/E 50.49LNTH P/E 24.54SUPN ROE -4.14%BHC key statisticsAll Drug Manufacturers - Specialty & Generic stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.